Colin Bristow
Stock Analyst at UBS
(1.25)
# 3,358
Out of 4,778 analysts
92
Total ratings
35.19%
Success rate
-12.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $4.63 | +51.19% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.14 | +7.12% | 13 | Feb 5, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $4 → $2.2 | $0.69 | +218.84% | 5 | Jan 27, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $92.31 | +30.00% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $57.03 | +24.50% | 3 | Dec 3, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $96 | $106.74 | -10.06% | 3 | Nov 21, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $562 → $586 | $511.74 | +14.51% | 13 | Nov 5, 2024 | |
| AMGN Amgen | Maintains: Neutral | $335 → $326 | $314.38 | +3.70% | 7 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Neutral | $234 → $202 | $141.60 | +42.66% | 10 | Oct 3, 2024 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $14 → $6 | $1.24 | +383.87% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $41 | $19.44 | +110.91% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $2.29 | +598.69% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $661.00 | +66.26% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $54 | $8.73 | +518.56% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $76.33 | +118.79% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $864.90 | -51.44% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $9.02 | -77.83% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.02 | +1,664.71% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $209.17 | -30.20% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $61.05 | +22.85% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.22 | +1,071.17% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $8.66 | +3.93% | 1 | Aug 23, 2021 |
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $4.63
Upside: +51.19%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.14
Upside: +7.12%
ALX Oncology Holdings
Jan 27, 2025
Maintains: Buy
Price Target: $4 → $2.2
Current: $0.69
Upside: +218.84%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $92.31
Upside: +30.00%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $57.03
Upside: +24.50%
Gilead Sciences
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $106.74
Upside: -10.06%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Buy
Price Target: $562 → $586
Current: $511.74
Upside: +14.51%
Amgen
Oct 31, 2024
Maintains: Neutral
Price Target: $335 → $326
Current: $314.38
Upside: +3.70%
Biogen
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $141.60
Upside: +42.66%
Acumen Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $14 → $6
Current: $1.24
Upside: +383.87%
Aug 13, 2024
Maintains: Buy
Price Target: $42 → $41
Current: $19.44
Upside: +110.91%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $2.29
Upside: +598.69%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $661.00
Upside: +66.26%
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $8.73
Upside: +518.56%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $76.33
Upside: +118.79%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $864.90
Upside: -51.44%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $9.02
Upside: -77.83%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.02
Upside: +1,664.71%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $209.17
Upside: -30.20%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $61.05
Upside: +22.85%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.22
Upside: +1,071.17%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $8.66
Upside: +3.93%